Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CADENCE-1
NCT03688685Phase 2Completed
- Sponsor
- Cadent Therapeutics
- Start
- Jan 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rimtuzalcap in essential tremor (ET), sponsored by Cadent Therapeutics. Primary endpoint: Treatment Emergent Adverse Events. Started Jan 2019; status: completed.
02
Drugs
rimtuzalcap
03
Conditions
essential tremor (ET)
Beyond the preview
Go deeper on NCT03688685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03688685.